



US005629294A

**United States Patent** [19]  
**diZerega et al.**

[11] **Patent Number:** **5,629,294**  
[45] **Date of Patent:** **May 13, 1997**

- [54] **COMPOSITIONS AND METHODS FOR PREVENTING ADHESION FORMATION**
- [75] Inventors: **Gere S. diZerega**, Pasadena; **Kathleen E. Rodgers**, Long Beach, both of Calif.
- [73] Assignee: **University of Southern California**, Los Angeles, Calif.
- [21] Appl. No.: **178,482**
- [22] Filed: **Jan. 6, 1994**

**Related U.S. Application Data**

- [63] Continuation of Ser. No. 789,231, Nov. 7, 1991, abandoned.
- [51] **Int. Cl.<sup>6</sup>** ..... **A61K 38/00**; A61K 38/02; C07K 5/00; C07K 7/00
- [52] **U.S. Cl.** ..... **514/18**; 514/9; 514/15; 514/16; 514/17; 530/300; 530/327; 530/328; 530/329; 530/330
- [58] **Field of Search** ..... 514/15, 16, 17, 514/18, 9; 530/300, 331, 330, 329, 328, 327

**References Cited**

**U.S. PATENT DOCUMENTS**

4,517,686	5/1985	Ruoslahti et al.	623/1
4,578,079	3/1986	Ruoslahti et al.	623/11
4,589,881	5/1986	Pierschbacher et al.	623/11
4,614,517	9/1986	Ruoslahti et al.	530/330
4,661,111	4/1987	Ruoslahti et al.	623/11
4,746,508	5/1988	Carey et al.	424/88
4,792,525	12/1988	Ruoslahti et al.	435/240.243
4,857,508	8/1989	Adams et al.	514/18
5,100,875	3/1992	Marguerie de Rotrou	514/18
5,169,833	12/1992	Hansen, Jr. et al.	514/17
5,352,664	10/1994	Camey et al.	514/13

**FOREIGN PATENT DOCUMENTS**

0380370	8/1990	European Pat. Off.	A61K 31/395
0422938A1	4/1991	European Pat. Off.	.
0422937A1	4/1991	European Pat. Off.	.

**OTHER PUBLICATIONS**

Ruoslahti et al, *Cell*, vol. 44, Feb. 28, 1986, pp. 517-518.  
 STN international, *Fastnotes*, c/o Chemical Abstracts Service pp. 1-2.  
 Jun et al., *Chemical Abstracts*, vol. 111, 1989, Nov. 20, No. 21, Abstract No: 192366c.  
 Aumailley et al, *FEBS Letts*, vol. 291, No. 1, Oct. 1991, pp. 50-54.  
*Experimental Cell Research*, vol. 190, 1990, pp. 17-24, Katow et al.  
*Progress in Developmental Biology Part B*, vol. 217B, 1986, pp. 235-238 Poole et al.  
 Basson et al., "Spatiotemporal Segregation of Endothelial Cell Integrin and Nonintegrin Extracellular Matrix-binding Proteins during Adhesion Events:", *J. Cell Biol.* 110:789-801 (Mar., 1990).  
 Nishimura et al., "Ibuprofen in the Prevention of Experimentally Induced Postoperative Adhesions", *Am. J. of Med.* 77:102-106 (1984).  
 Sipes et al., "RGD Supported Corneal Wound Healing", *J. of Cellular Biochem. Suppl.* 15F:184 (1991).

Krissansen et al., "Identification of a Novel Integrin  $\beta$  Subunit Expressed on /Cultured Monocytes (Macrophages)", *J. Biol. Chem.* 265:823-830 (1990).  
 Gresham et al., "A Novel Member of the Integrin Receptor Family Mediates Arg-Gly-Asp-simulated Neutrophil Phagocytosis", *J. Cell. Biol.* 108:1935-1943 (1989).  
 Brown, E.L. and Goodwin, J.L., "Fibronectin Receptors of Phagocytes: Characterization of the ARG-Gly-Asp Binding Proteins of Human Monocytes and Polymorphonuclear Leukocytes", *Journal of Experimental Medicine* 167:777-93 (1988).  
 Wright et al., "C3bi Receptor (Complement Type 3) Recognizes a Region of Complement Protein C3 Containing the Sequence Arg-Gly-Asp", *Proc. Nat'l Acad. Sci.* 84:1965-1968 (1987).  
 Ruggeri et al., "Inhibition of Platelet Function with Synthetic Peptides Designed to be High-affinity Antagonists of Fibrinogen Binding to Platelets", *Proceedings Natl. Acad. Sciences* 83:5708-5712 (1986).  
 Diamond et al., "Synergistic Effects of INTERCEED (TC7) and Heparin in Reducing Adhesion Formation in the Rabbit Uterine Horn Model", *Fertility and Sterility* 55:389 (1991).  
 Abe et al., "The Effect of Intraperitoneal Administration of Sodium Tolmetin-HNyaluronic Acid on the Postsurgical Cell Infiltration in vivo", *J. Surg. Res.* 49:322 (1990).  
 Rodgers et al., "Inhibition of Postsurgical Adhesions by Liposomes Containing Nonsteroidal Antiinflammatory Drugs", *Int. J. Fertil.* 35:40 (1990).  
 Hoeckel et al., "Prevention of Peritoneal Adhesions in the Rat With Sustained Intraperitoneal Dexamethasone Delivered by a Novel Therapeutic System", *Annales Chirurgiae et Gynaecologiae* 76:306-313 (1987).  
 Lewis, D.H., "Controlled Release of Bioactive Agents From Lactide/Blycolide Polymers", Jason & Langer (eds), *Biodegradable Polymers as Drug Delivery Systems*, pp. 1-41 (1990).  
 Ruoslahti, E., "Fibronectin and Its Receptors", *Ann. Rev. Biochem.* 57:375-413 (1988).  
 Ruoslahti, E., "Versatile Mechanisms of Cell Adhesion", *The Harvey Lectures*, Series 84, pp. 1-17 (1990).  
 Cadroy et al., "RGDV Peptide Selectively Inhibits Platelet-dependent Thrombus Formation in Vivo", *J. Clin. Invest.* 84:939-944 (1989).  
 Rodgers, K., "Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) In the Treatment of Postsurgical Adhesion", *Progress in Clinical and Biological Research* 358:119-129 (1990).

*Primary Examiner*—Avis M. Davenport  
*Attorney, Agent, or Firm*—Robbins, Berliner & Carson, LLP

[57] **ABSTRACT**

Compositions and methods for prevention of adhesion formation, whereby an effective amount of one or more adhesion preventing RGD-containing peptides is administered for a period of time sufficient to permit tissue repair. The RGD-containing peptide is further characterized in that it inhibits platelet aggregation and does not induce inflammation or trauma at the site of administration. The RGD-containing peptide is preferably administered in conjunction with a delivery vehicle (e.g., microcapsules, microspheres, liposomes, viscous instillates and absorbable mechanical barriers) useful for maintaining local concentrations of the peptide at an effective level.

**15 Claims, No Drawings**